Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
NEW YORK, Nov. 15, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Diplomat Pharmacy, Inc. (NYSE:DPLO) securities between October 9, 2014 and November 2, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/diplomat-pharmacy. There is no cost or obligation to you.
According to the complaint, during the Class Period, Diplomat Pharmacy issued false and misleading statements to investors and/or failed to disclose that: (1) the Company lacked adequate internal controls over its financial reporting and thus could not adequately calculate DIR fees; (2) Diplomat Pharmacy’s hepatitis C segment was not performing as previously disclosed to investors; (3) the Company overstated its full-year 2016 guidance; and (4) as a result of the above, Diplomat Pharmacy’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
On November 2, 2016, Diplomat Pharmacy announced third quarter 2016 results that were below investors’ expectations and lowered its full year 2016 guidance. When this news was announced, shares of Diplomat Pharmacy fell in value, harming investors.
If you suffered a loss in Diplomat Pharmacy you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/diplomat-pharmacy.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
